» Articles » PMID: 10456907

Pseudomonas Aeruginosa Exoenzyme S Stimulates Murine Lymphocyte Proliferation in Vitro

Overview
Journal Infect Immun
Date 1999 Aug 24
PMID 10456907
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The exuberant immunoinflammatory response that is associated with Pseudomonas aeruginosa infection is the major source of the morbidity and mortality in cystic fibrosis (CF) patients. Previous studies have established that an exoproduct of P. aeruginosa (exoenzyme S) is a mitogen for human T lymphocytes and activates a larger percentage of T cells than most superantigens, which may contribute to the immunoinflammatory response. An animal model would facilitate studies of the pathophysiologic consequences of this activation. As a first step toward developing an animal model, the murine lymphocyte response to exoenzyme S was examined. When stimulated with exoenzyme S, splenocytes isolated from naive mice entered S phase and proliferated. The optimum response occurred after 2 to 3 days in culture, at 4 x 10(5) cells per well and 5.0 micrograms of exoenzyme S per ml. The response was not due to lipopolysaccharide, since Rhodobacter sphaeroides lipid A antagonist did not block the response. Other preparations of exoenzyme S stimulated lymphocyte proliferation, since the response to recombinant exoenzyme S (rHisExo S) cloned from strain 388 was similar to the response to exoenzyme S from strain DG1. There was evidence that genetic variability influenced the response, since A/J, CBA/J, and C57BL/6 mice were high responders and BALB/cJ mice were low responders following stimulation with exoenzyme S. Both splenic T and B lymphocytes entered the cell cycle in response to exoenzyme S. Thus, murine lymphocytes, like human lymphocytes, respond to P. aeruginosa exoenzyme S, which supports the development of a murine model that may facilitate our understanding of the role that exoenzyme S plays in the pathogenesis of P. aeruginosa infections in CF patients.

Citing Articles

Abnormal functional lymphoid tolerance and enhanced myeloid exocytosis are characteristics of resting and stimulated PBMCs in cystic fibrosis patients.

Gaudin C, Ghinnagow R, Lemaire F, Villeret B, Sermet-Gaudelus I, Sallenave J Front Immunol. 2024; 15:1360716.

PMID: 38469306 PMC: 10925672. DOI: 10.3389/fimmu.2024.1360716.


The impact of host genetic background in the Pseudomonas aeruginosa respiratory infections.

Lore N, Cigana C, Sipione B, Bragonzi A Mamm Genome. 2018; 29(7-8):550-557.

PMID: 29947963 PMC: 7087806. DOI: 10.1007/s00335-018-9753-8.


Pre-transplant Panel Reactive Antibody and Survival in Adult Cystic Fibrosis Patients After Lung Transplantation.

Hayes Jr D, Tumin D, Tobias J Lung. 2016; 194(3):429-35.

PMID: 26932810 DOI: 10.1007/s00408-016-9861-8.


The ADP-ribosyltransferase domain of the effector protein ExoS inhibits phagocytosis of Pseudomonas aeruginosa during pneumonia.

Rangel S, Logan L, Hauser A mBio. 2014; 5(3):e01080-14.

PMID: 24917597 PMC: 4056551. DOI: 10.1128/mBio.01080-14.


Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosis.

Di Bonaventura G, Pompilio A, Zappacosta R, Petrucci F, Fiscarelli E, Rossi C Infect Immun. 2010; 78(6):2466-76.

PMID: 20308302 PMC: 2876550. DOI: 10.1128/IAI.01391-09.


References
1.
Woods D, Sokol P . Use of transposon mutants to assess the role of exoenzyme S in chronic pulmonary disease due to Pseudomonas aeruginosa. Eur J Clin Microbiol. 1985; 4(2):163-9. DOI: 10.1007/BF02013591. View

2.
Nicas T, Frank D, Stenzel P, Lile J, Iglewski B . Role of exoenzyme S in chronic Pseudomonas aeruginosa lung infections. Eur J Clin Microbiol. 1985; 4(2):175-9. DOI: 10.1007/BF02013593. View

3.
Nicas T, Bradley J, Lochner J, Iglewski B . The role of exoenzyme S in infections with Pseudomonas aeruginosa. J Infect Dis. 1985; 152(4):716-21. DOI: 10.1093/infdis/152.4.716. View

4.
Sadick M, Locksley R, Tubbs C, Raff H . Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro. J Immunol. 1986; 136(2):655-61. View

5.
Woods D, Que J . Purification of Pseudomonas aeruginosa exoenzyme S. Infect Immun. 1987; 55(3):579-86. PMC: 260377. DOI: 10.1128/iai.55.3.579-586.1987. View